China Meheco subsidiary wins drug approval, parent waives equity stake

China Meheco's subsidiary Tianfang Pharmaceutical received drug registration approval for Fudostin tablets from the National Medical Products Administration. The respiratory disease treatment had cumulative R&D investment of approximately 11.61 million yuan.

Separately, China Meheco shareholders approved waiving the priority right to purchase a 24% equity stake in an associate company.